Your browser doesn't support javascript.
loading
18FDG positron emission tomography mining for metabolic imaging biomarkers of radiation-induced xerostomia in patients with oropharyngeal cancer.
Elhalawani, Hesham; Cardenas, Carlos E; Volpe, Stefania; Barua, Souptik; Stieb, Sonja; Rock, Calvin B; Lin, Timothy; Yang, Pei; Wu, Haijun; Zaveri, Jhankruti; Elgohari, Baher; Abdallah, Lamiaa E; Jethanandani, Amit; Mohamed, Abdallah S R; Court, Laurence E; Hutcheson, Katherine A; Brandon Gunn, G; Rosenthal, David I; Frank, Steven J; Garden, Adam S; Rao, Arvind; Fuller, Clifton D.
Afiliação
  • Elhalawani H; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Cardenas CE; Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA, United States.
  • Volpe S; Department of Radiation Physics, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Barua S; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Stieb S; Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy.
  • Rock CB; Department of Electrical and Computer Engineering, Rice University, Houston, TX, United States.
  • Lin T; Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, United States.
  • Yang P; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Wu H; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Zaveri J; Department of Radiation Oncology, University of Utah Huntsman Cancer Institute, Salt Lake City, UT, United States.
  • Elgohari B; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Abdallah LE; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Jethanandani A; Key Laboratory of Translational Radiation Oncology, Hunan Cancer Hospital, Xiangya Medical School, Central South University, Changsha, China.
  • Mohamed ASR; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Court LE; Department of Head and Neck Surgery, Section of Speech Pathology and Audiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Hutcheson KA; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Brandon Gunn G; Department of Clinical Oncology & Nuclear Oncology, Mansoura University, Mansoura, Egypt.
  • Rosenthal DI; Department of Clinical Oncology & Nuclear Oncology, Ain Shams University, Cairo, Egypt.
  • Frank SJ; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Garden AS; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Rao A; Department of Radiation Physics, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Fuller CD; Department of Head and Neck Surgery, Section of Speech Pathology and Audiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Clin Transl Radiat Oncol ; 29: 93-101, 2021 Jul.
Article em En | MEDLINE | ID: mdl-34195391
ABSTRACT

PURPOSE:

Head and neck cancers radiotherapy (RT) is associated with inevitable injury to parotid glands and subsequent xerostomia. We investigated the utility of SUV derived from 18FDG-PET to develop metabolic imaging biomarkers (MIBs) of RT-related parotid injury.

METHODS:

Data for oropharyngeal cancer (OPC) patients treated with RT at our institution between 2005 and 2015 with available planning computed tomography (CT), dose grid, pre- & first post-RT 18FDG-PET-CT scans, and physician-reported xerostomia assessment at 3-6 months post-RT (Xero 3-6 ms) per CTCAE, was retrieved, following an IRB approval. A CT-CT deformable image co-registration followed by voxel-by-voxel resampling of pre & post-RT 18FDG activity and dose grid were performed. Ipsilateral (Ipsi) and contralateral (contra) parotid glands were sub-segmented based on the received dose in 5 Gy increments, i.e. 0-5 Gy, 5-10 Gy sub-volumes, etc. Median and dose-weighted SUV were extracted from whole parotid volumes and sub-volumes on pre- & post-RT PET scans, using in-house code that runs on MATLAB. Wilcoxon signed-rank and Kruskal-Wallis tests were used to test differences pre- and post-RT.

RESULTS:

432 parotid glands, belonging to 108 OPC patients treated with RT, were sub-segmented & analyzed. Xero 3-6 ms was reported as non-severe (78.7%) and severe (21.3%). SUV- median values were significantly reduced post-RT, irrespective of laterality (p = 0.02). A similar pattern was observed in parotid sub-volumes, especially ipsi parotid gland sub-volumes receiving doses 10-50 Gy (p < 0.05). Kruskal-Wallis test showed a significantly higher mean RT dose in the contra parotid in the patients with more severe Xero 3-6mo (p = 0.03). Multiple logistic regression showed a combined clinical-dosimetric-metabolic imaging model could predict the severity of Xero 3-6mo; AUC = 0.78 (95%CI 0.66-0.85; p < 0.0001).

CONCLUSION:

We sought to quantify pre- and post-RT 18FDG-PET metrics of parotid glands in patients with OPC. Temporal dynamics of PET-derived metrics can potentially serve as MIBs of RT-related xerostomia in concert with clinical and dosimetric variables.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article